本文選題：酪氨酸激酶抑制劑AG + 喉癌Hep-細胞　； 參考：《臨床耳鼻咽喉頭頸外科雜志》2014年18期

【摘要】：目的:通過體外實驗檢測酪氨酸酶抑制劑AG825對Hep-2細胞增殖及凋亡的影響,并探討其作用機制。方法:通過MTT法觀察酪氨酸酶抑制劑AG825在不同濃度及時間時對Hep-2細胞的增殖抑制作用;流式細胞儀檢測其早期凋亡率;Western blot技術(shù)檢測細胞內(nèi)信號傳導分子的表達水平的變化。結(jié)果:不同濃度的AG825對Hep-2細胞增殖均具有抑制作用,并且隨著藥物濃度的增大及作用時間的延長,抑制作用逐漸增強。流式細胞學檢測顯示:AG825促進了Hep-2細胞的早期凋亡,并具有劑量依賴性。Western blot結(jié)果顯示:AG825作用以后,表皮生長因子下游的信號傳導蛋白因子p-Akt和p-MAPK表達水平明顯降低,并且隨著藥物濃度的增大,下游的信號傳導因子的表達水平依次下降。結(jié)論:酪氨酸激酶抑制劑AG825能有效的抑制Hep-2細胞的生長,并促進細胞的早期凋亡。
[Abstract]:Aim: to investigate the effects of tyrosinase inhibitor AG825 on the proliferation and apoptosis of Hep-2 cells in vitro. Methods: the inhibitory effect of tyrosinase inhibitor AG825 on the proliferation of Hep-2 cells at different concentrations and time was observed by MTT assay, and the expression of signal transduction molecules in Hep-2 cells was detected by flow cytometry and Western blot. Results: AG825 at different concentrations could inhibit the proliferation of Hep-2 cells, and the inhibitory effect was gradually enhanced with the increase of drug concentration and the prolongation of action time. Flow cytometric analysis showed that: AG825 promoted the early apoptosis of Hep-2 cells. The results of Western blot in a dose-dependent manner showed that the expression of signaling protein factor p-Akt and p-MAPK in the downstream of epidermal growth factor (EGF) was significantly decreased after treated with WAG825. And with the increase of drug concentration, the expression level of downstream signal transduction factor decreased in turn. Conclusion: AG825, a tyrosine kinase inhibitor, can effectively inhibit the growth of Hep-2 cells and promote the early apoptosis of Hep-2 cells.
【作者單位】： 遼寧醫(yī)學院附屬第一醫(yī)院耳鼻咽喉科;
【基金】：遼寧省計劃項目課題——SOCS1沉默增強DC靶向抗喉癌免疫治療的研究資助(No:2012225019)
【分類號】：R739.65

【參考文獻】

相關(guān)期刊論文 前4條

1 賈剛;張為民;;表皮生長因子酪氨酸激酶抑制劑抑制腫瘤細胞生長的機制[J];廣東醫(yī)學;2008年06期

2 劉靖;王林;楊曉明;;多靶點蛋白酪氨酸激酶抑制劑的研究進展[J];國際藥學研究雜志;2009年03期

3 茅培英,張進川,于曉Y，

本文編號：2025272